Domain Therapeutics Bolsters IP for Treg Depleting anti-CCR8 Antibodies, Featuring DT-7012

Domain Therapeutics, a global clinical-stage biopharmaceutical company, has recently announced the publication of three international Patent Cooperation Treaty (PCT) patent applications. These patents are set to significantly enhance the company’s intellectual property portfolio, specifically regarding its series of Treg depleting anti-CCR8 antibodies. This new development marks a noteworthy advancement in the company’s strategy to protect and advance its innovative drug candidates in the field of immuno-oncology.

The patents are particularly focused on antibodies that target the CCR8 protein, a G Protein-Coupled Receptor (GPCR) specifically expressed by tumor-infiltrating regulatory T cells (Tregs). These Tregs are notable for their immunosuppressive functions within the tumor microenvironment, which contribute to the ineffectiveness of various cancer therapies. By depleting these Tregs, Domain’s anti-CCR8 antibodies aim to enhance the body’s immune response against tumors, thereby improving clinical outcomes for cancer patients.

One of the standout candidates in Domain’s CCR8 antibody series is DT-7012. This drug is currently in the pre-IND (Investigational New Drug) stage and is anticipated to enter Phase I clinical trials in early 2025. The publication of these patents is a crucial step in solidifying the company's market position and offering robust protection for its innovative treatments.

Stephan Schann, Domain Therapeutics’ Chief Scientific Officer, emphasized the importance of these patents in the company’s strategy. He noted that the patents not only bolster the company’s robust intellectual property estate but also extend its influence across various international markets. Schann highlighted that these patents are integral to the company’s lead anti-CCR8 candidate, DT-7012, and reinforce Domain’s status as a leader in GPCR-mediated immunotherapies.

The strategic focus on CCR8 as a target is highly significant. The CCR8 protein is primarily expressed by Tregs within the tumor environment—cells that are key players in immune suppression and the failure of many cancer treatments. By specifically targeting and depleting these cells, Domain Therapeutics aims to develop more effective immunotherapies that can overcome the limitations of current treatments and significantly improve patient outcomes.

This move aligns with Domain’s broader objectives in the field of immuno-oncology. The company is actively accelerating and expanding its research and development efforts to create innovative therapies that address the challenges posed by tumor-induced immunosuppression. By targeting GPCR-driven immuno-resistance, Domain aims to unlock new therapeutic opportunities and deliver cutting-edge treatments to cancer patients worldwide.

Overall, the recent publication of these three international patents marks a significant milestone for Domain Therapeutics. It not only strengthens their intellectual property portfolio but also underscores their commitment to advancing the field of immuno-oncology. With the potential of DT-7012 and other anti-CCR8 antibodies, Domain is poised to make a substantial impact on cancer treatment, offering new hope to patients and healthcare providers alike.